|

Alleviant ALLAY-HFrEF Study

RECRUITINGN/ASponsored by Alleviant Medical, Inc.
Actively Recruiting
PhaseN/A
SponsorAlleviant Medical, Inc.
Started2025-03-10
Est. completion2028-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations40 sites

Summary

Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* LVEF ≤ 40%
* NYHA class II, III or ambulatory IV HF
* Receiving optimal, maximally tolerated, stable GDMT

Exclusion Criteria:

* Advanced heart failure
* Life-expectancy \< 12 months
* Evidence of right heart dysfunction

Conditions2

Heart DiseaseHeart Failure

Locations40 sites

Keck Medical Center of USC
Michael Fong, MD
University California Los Angeles Medical Center
Richard Cheng, MD
UC Davis Medical Center
Tai Pham, MD
Scripps Clinical Research Services
Rajeev Mohan, MD
University of California San Francisco
Liviu Klein, MD

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.